Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Alone and With 5-Azacytidine in CD30+ AML
NCT02096042Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2014
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brentuximab vedotin in acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 120 days. Started Apr 2014; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02096042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096042.